Nightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF) estimates that it has exceeded its revenue target for the financial year 1 July 2024 – 30 June 2025 despite operating in a highly challenging global market environment. However, due to its investments in global business expansion, the company estimates that it will not meet its adjusted EBITDA target for the financial year. Nightingale Health had set a target to increase revenue and improve its adjusted EBITDA compared to the previous financial year.

The global economic uncertainty, particularly in the U.S. market, created external challenges that impacted Nightingale Health’s revenue performance in the financial year 2024–2025. Despite these challenges, Nightingale Health succeeded in increasing sales and is estimating revenue growth of up to 15% compared to the previous financial year.

During the financial year 2024–2025 the company continued investing in long-term growth, including the construction and launch of a new laboratory in New York and expansion efforts in Singapore and Europe. As a result of these essential growth investments, Nightingale Health estimates that its adjusted EBITDA will decline by up to 15% compared to the previous financial year. Adjusted EBITDA means EBITDA subtracted by share-based payments, extraordinary items and items affecting comparability.

The deviations in revenue and adjusted EBITDA compared to the previous financial year will not impact the company’s financial position or future plans.

Nightingale Health will publish its financial statements release for the financial year 2024–2025 on 18 September 2025.